Using Fourier Transform Infrared spectroscopy (FTIR), it is possible to show chemical composition of materials and / or profile chemical changes occurring in tissues, cells, and body fluids during onset and progression of diseases. For diagnostic application, the use of blood would be the most appropriate in biospectroscopy studies since, (i) it is easily accessible and, (ii) enables frequent analyses of biochemical changes occurring in pathological states. At present, different studies have investigated potential of serum, plasma and sputum being alternative biofluids for lung cancer detection using FTIR. However, until now, it has not been shown which biofluid; among serum and plasma, that can serve as the best material medium for detecting lung cancer with highest levels of accuracy. In this study, plasma and serum isolated from blood consenting participants without lung cancer symptoms (controls) and lung cancer patients. The samples were measured using FTIR and subsequently analyzed by machine learning (ML) algorithms in order to show which fluids (serum or plasma) would better enhance detection of lung cancer. Higher absorbances values of PO, CH, CH and amides vibrations in FTIR spectra of both serum and plasma samples, collected from lung cancer patients were observed in comparison to individuals without lung cancer symptoms (controls). Principal component analysis (PCA) of FTIR spectra showed plasma and serum samples collected from lung cancer patients and individuals without lung cancer symptoms were better differentiated in fingerprinting region (from 800 to 1800 cm) when compared to lipid region (2800-3000 cm). Moreover, also sensitivity specificity and accuracy calculated by logistic regression (LR) and receive operating characteristic (ROC) showed higher values for fingerprint range (800-1800 cm) in comparison with lipids (2800-3000 cm) one for both, serum and plasma. However, using these methods differences between serum and plasma were not existed. From the all obtained results, it was visible, that both fluids could be used in detected lung cancer using FTIR. Moreover, it was also showed that fingerprint range gave a better distinction between the studied patient groups than the lipid range. This was noticeable for both serum and plasma.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-024-81649-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686151PMC

Publication Analysis

Top Keywords

lung cancer
44
serum plasma
32
cancer symptoms
12
cancer patients
12
lung
11
cancer
11
serum
10
plasma
9
body fluids
8
detection lung
8

Similar Publications

Limited data exist on cancer screening in carceral facilities. This study evaluates the feasibility and outcomes of a population-based lung cancer screening initiative in a carceral setting. This is a retrospective review of a lung cancer screening event at the Rhode Island Department of Corrections.

View Article and Find Full Text PDF

Importance: Research indicates that social drivers of health are associated with cancer screening adherence, although the exact magnitude of these associations remains unclear.

Objective: To investigate the associations between individual-level social risks and nonadherence to guideline-recommended cancer screenings.

Design, Setting, And Participants: This cross-sectional study used 2022 Behavioral Risk Factor Surveillance System data from 39 US states and Washington, DC.

View Article and Find Full Text PDF

Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.

Cancer Immunol Immunother

January 2025

Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.

The combined use of tocilizumab (TCZ) and immune checkpoint inhibitors (ICIs) in cancer treatment is gaining attention, but preclinical studies are lacking. Our study aims to investigate the synergistic anti-tumor effect of TCZ combined with ICIs and its role in treating immune-related adverse events (irAEs). The clinical significance of high interleukin-6 (IL-6) expression in tumor patients was analyzed from the Cancer Genome Atlas (TCGA) database.

View Article and Find Full Text PDF

Therapeutic effect of fully human anti-Nrp-1 antibody on non-small cell lung cancer in vivo and in vitro.

Cancer Immunol Immunother

January 2025

Public Center of Experimental Technology, The School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan Province, China.

Although immune checkpoint inhibitors have changed the treatment paradigm for non-small cell lung cancer (NSCLC), not all patients benefit from them. Therefore, there is an urgent need to explore novel immune checkpoint inhibitors. Neuropilin-1 (Nrp-1) is a unique immune checkpoint capable of exerting antitumor effects through CD8 T cells.

View Article and Find Full Text PDF

Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer.

Cancer Immunol Immunother

January 2025

Department of Oncology, Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, 222002, China.

Background: Due to its strong immunogenicity and tumor specificity, neoplastic antigen has emerged as an immunotherapy target with wide therapeutic prospect and clinical application value. Anti-programmed death-1 (PD-1) antibodies reinvigorate T cell-mediated antitumor immunity. So, we conducted single-arm trial to assess the safety and efficacy of PD-1 blockade(Camrelizumab)-activated neoantigen specific cellular therapy (aNASCT) on advanced relapsed non-small lung cancer(NSCLC)(ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!